Sökning: onr:"swepub:oai:gup.ub.gu.se/89643" >
Compounds with affi...
Compounds with affinity for serotonergic receptors in the treatment of premenstrual dysphoria: a comparison of buspirone, nefazodone and placebo.
-
- Landén, Mikael, 1966 (författare)
- Gothenburg University,Göteborgs universitet,Institutionen för klinisk neurovetenskap, Sektionen för psykiatri,Institute of Clinical Neurosciences, Section of Psychiatry
-
Eriksson, O (författare)
-
- Sundblad-Elverfors, Charlotta, 1959 (författare)
- Gothenburg University,Göteborgs universitet,Institutionen för fysiologi och farmakologi, Avdelningen för farmakologi,Institute of Physiology and Pharmacology, Dept of Pharmacology
-
visa fler...
-
- Andersch, Björn (författare)
- Gothenburg University,Göteborgs universitet,Institutionen för kvinnors och barns hälsa, Avdelningen för obstetrik och gynekologi,Institute for the Health of Women and Children, Dept of Obstetrics and Gynaecology
-
Naess?n, T (författare)
-
- Eriksson, Elias, 1956 (författare)
- Gothenburg University,Göteborgs universitet,Institutionen för fysiologi och farmakologi, Avdelningen för farmakologi,Institute of Physiology and Pharmacology, Dept of Pharmacology
-
visa färre...
-
(creator_code:org_t)
- 2001
- 2001
- Engelska.
-
Ingår i: Psychopharmacology. - 0033-3158. ; 155:3, s. 292-8
- Relaterad länk:
-
https://gup.ub.gu.se...
Abstract
Ämnesord
Stäng
- RATIONALE: It is well established that serotonin reuptake inhibitors (SRIs) are effective for the treatment of premenstrual dysphoria (PMD), but the receptor subtype(s) mediating this effect of serotonin have yet not been identified. OBJECTIVE: In this trial, the possible efficacy of buspirone, a partial 5HT1A receptor agonist, and nefazodone, a combined SRI and 5HT2 receptor antagonist, was evaluated in women with PMD. METHODS: After a three-menstrual-cycle screening phase, patients were randomised to buspirone (n=19), nefazodone (n=22) or placebo (n=22). During the first two treatment cycles, patients were taking the drug during the luteal phase only (mean +/- SD daily dose of buspirone: 21 +/- 6 mg; nefazodone: 228 +/- 54 mg). During the subsequent two cycles, the medication was taken each day of the menstrual cycle (mean daily dose of buspirone: 27 +/- 10 mg; nefazodone: 304 +/- 95 mg). RESULTS: With respect to self-rated global improvement, buspirone (P<0.001) but not nefazodone was significantly superior to placebo. While buspirone appeared to reduce self-rated irritability (visual analogue scale) more effectively than placebo, other self-rated symptoms did not differ markedly between the groups. The side-effects were mild, and sexual dysfunction was not significantly more common in patients given buspirone or nefazodone than in those given placebo. CONCLUSION: It is suggested that buspirone is mildly effective for premenstrual irritability. In patients experiencing sexual dysfunction when treated with an SRI, buspirone may be a useful alternative.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Medicinska och farmaceutiska grundvetenskaper -- Farmakologi och toxikologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Basic Medicine -- Pharmacology and Toxicology (hsv//eng)
Nyckelord
- Adult
- Buspirone
- administration & dosage
- adverse effects
- therapeutic use
- Double-Blind Method
- Female
- Humans
- Premenstrual Syndrome
- drug therapy
- psychology
- Psychiatric Status Rating Scales
- Receptors
- Serotonin
- drug effects
- Serotonin Agonists
- administration & dosage
- adverse effects
- therapeutic use
- Treatment Outcome
- Triazoles
- administration & dosage
- adverse effects
- therapeutic use
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas